PROGRESSION FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN PATIENTS RECEIVING 3 TARGETED THERAPIES (TTS) FOR METASTATIC RENAL-CELL CARCINOMA (MRCC)

被引：0

作者：

Iacovelli, R. ^{[1
]}

Santoni, M. ^{[2
]}

Di Lorenzo, G. ^{[3
]}

Cerbone, L. ^{[4
]}

Aglietta, M. ^{[5
]}

Masini, C. ^{[6
]}

Giganti, M. O. ^{[7
]}

Messina, C. ^{[8
]}

Sternberg, C. N. ^{[9
]}

Procopio, G. ^{[10
]}

机构：

[1] Univ Roma La Sapienza, Dept Radiol Oncol & Human Pathol, Rome, Italy

[2] Univ Politecn Marche, Ancona, Italy

[3] Univ Federico II, Cattedra Oncol Med, Dept Oncol, Naples, Italy

[4] San Camillo & Forlanini Hosp, Rome, Italy

[5] Fdn Piemontese Ric Cancro Onlus, Div Oncol & Ematol, Candiolo, Italy

[6] Osped Policlin Modena, Dept Hematol Oncol, Modena, Italy

[7] Niguarda Ca Grande Hosp, Milan, Italy

[8] Osped Riuniti Bergamo, I-24100 Bergamo, Italy

[9] San Camillo Forlanini Hosp, Rome, Italy

[10] Ist Nazl Tumori, Fdn IRCCS, I-20133 Milan, Italy

来源：

ANNALS OF ONCOLOGY | 2012年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：270 / 271

页数：2

共 50 条

[41] Prognostic factors for survival in patients with metastatic renal cell carcinoma treated with targeted therapies
G Procopio
E Verzoni
R Iacovelli
D Biasoni
I Testa
L Porcu
F De Braud
British Journal of Cancer, 2012, 107 : 1227 - 1232
[42] Prognostic factors for survival in patients with metastatic renal cell carcinoma treated with targeted therapies
Procopio, G.
Verzoni, E.
Iacovelli, R.
Biasoni, D.
Testa, I.
Porcu, L.
De Braud, F.
BRITISH JOURNAL OF CANCER, 2012, 107 (08) : 1227 - 1232
[43] Inflammation-free survival as a surrogate endpoint for overall survival in patients with metastatic renal cell carcinoma
Harris, Wayne B.
Nickleach, Dana C.
Liu, Yuan
Kucuk, Omer
Master, Viraj A.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2014, 23 (11)
[44] Examining progression free survival (PFS), overall survival (OS), and toxicities of palbociclib in a geriatric population.
Clifton, Katherine
Kimmel, Jaime
Litton, Jennifer Keating
Tripathy, Debu
Sri, Meghan
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[45] Longer progression free survival with metastatic renal cell carcinoma
不详
ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2007, 45 (12): : B6 - B6
[46] Circadian robustness as an independent predictor of prolonged progression-free survival (PFS) and overall survival (OS) in 436 patients with metastatic colorectal cancer (mCRC).
Levi, Francis
Parganiha, Arti
Karaboue, Abdoulaye
Innominato, Pasquale F.
Giacchetti, Sylvie
Garufi, Carlo
Dispersyn, Garance
Focan, C. N. J.
Iacobelli, Stefano
Bjarnason, Georg A.
Moreau, Thierry
Dugue, Pierre Antoine
Waterhouse, Jim
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
[47] Evaluating the relationship between progression-free survival (PFS) and overall survival (OS) in clinical trials of patients (pts) with metastatic colorectal cancer (mCRC)
Sidhu, R.
Rong, A.
Dahlberg, S.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[48] EFFECT OF REDUCTION OF CIRCULATING TUMOR CELLS (CTCS) ON PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN METASTATIC BREAST CANCER (MBC) PATIENTS
Giuliano, M.
Giordano, A.
Handy, B. C.
Ueno, N.
Andreopoulou, E.
Alvarez, R. H.
Valero, V.
Hortobagyi, G. N.
Reuben, J.
Cristofanilli, M.
ANNALS OF ONCOLOGY, 2010, 21 : 32 - 33
[49] Impact of geographic region on overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC): Results from a pooled clinical trials database
Fay, Andre Poisl
Mckay, Rana R.
Lin, Xun
Sinnantov, Ronit
Choueiri, Toni K.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[50] PROGRESSION-FREE AND OVERALL SURVIVAL OF PATIENTS TREATED WITH PRESURGICAL SUNITINIB PRIOR TO CYTOREDUCTIVE NEPHRECTOMY (CN) IN CLEAR CELL SYNCHRONOUS METASTATIC RENAL CELL CARCINOMA (MRCC)
Bex, Axel
Blank, Christian
Chowdhury, Simon
Nichol, David
Peters, John
Horenblas, Simon
O'Brien, Tim
Sarwar, Naveed
Haanen, John
Powles, Thomas
JOURNAL OF UROLOGY, 2011, 185 (04): : E709 - E710

← 1 2 3 4 5 →